Jeroen Mebis, prof. dr.

CONTACT

Joy Lodewijckx, drs.

CONTACT

Lead Sponsor

Hasselt University

Collaborators

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•Informed Consent as documented by signature.
•Age 18 years or above
•Female
•Use of a wig for at least 2 hours a day
•Able to read and converse in Dutch
•Skin type I to IV on the Fitzpatrick Skin Type Scale
•Diagnosis of non-invasive (stage 0) or invasive (stage 1, 2 and 3A) breast adenocarcinoma.
•Treatment with neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy: anthracycline and taxane containing (paclitaxel or docetaxel) chemotherapy regimen.
•Diagnosed with CIA grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE)
•Have no documented or observable psychiatric or neurological disorders that might interfere with study participation (e.g., dementia or psychosis).

•Metastatic disease
•Severe or unstable cardio- respiratory or musculoskeletal disease
•Pregnancy
•Presence of cognitive impairment that might impact study outcomes
•Previously (before start of chemotherapy) diagnosed with a hair loss condition
•Receiving scalp cooling during chemotherapy
•Active infection on the scalp
•Chronic dermatologic condition (e.g. eczema, psoriasis, infection)
•Take any of the following medications for 6 months prior to initiation of the study: minoxidil, finasteride (or any other 5α-reductase inhibitor medications), medications with anti-androgenic properties (e.g. cyproterone, spironolactone, ketoconazole, flutamide and bicalutamide)n medications that can potentially cause hypertrichosis (ciclosporin, diazoxide, phenytoin and psoralens), and oral glucocorticoids